YPEL2 Inhibitors
YPEL2 inhibitors like Rapamycin, LY294002, and wortmannin, target the PI3K/AKT/mTOR pathway, which is critical for cellular growth and survival, and their inhibitory action can lead to decreased YPEL2 activity or expression. Similarly, compounds like U0126, SP600125, and SB203580 that inhibit MAPK signaling could alter YPEL2 functions, presuming its involvement in cell cycle control and apoptosis.
Trichostatin A, a histone deacetylase inhibitor, can change gene expression profiles, potentially affecting YPEL2 expression. Conversely, 17-AAG destabilizes proteins by inhibiting the chaperone protein Hsp90, which may include YPEL2 among its client proteins. Roscovitine targets cyclin-dependent kinases and may suppress YPEL2 activity by hindering cell division. Compounds that disrupt organelle function, such as brefeldin A and thapsigargin, can also indirectly impact YPEL2; brefeldin A interrupts protein trafficking, and thapsigargin triggers ER stress, both of which could modify YPEL2's cellular context and activity.Each chemical in the YPEL2 inhibitor class operates on distinct intracellular targets, indirectly influencing the functional landscape in which YPEL2 operates.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR signaling, which is crucial for cell growth and proliferation, potentially downregulating YPEL2 expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits PI3K, affecting AKT signaling and potentially reducing YPEL2 activity which could be downstream of this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, which could affect apoptosis and cell proliferation pathways involving YPEL2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAPK, potentially affecting stress response pathways and indirectly YPEL2's role in these pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor like LY294002, which could lead to lowered YPEL2 activity by affecting the AKT signaling pathway. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase inhibitor, which can alter gene expression and potentially decrease YPEL2 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor that can block ERK activation, potentially affecting the cellular processes regulated by YPEL2. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Inhibits cyclin-dependent kinases (CDKs), potentially reducing YPEL2 activity related to cell cycle control. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Induces ER stress and can affect calcium signaling, potentially altering cellular processes regulated by YPEL2. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts Golgi apparatus function, which could affect trafficking of proteins like YPEL2. | ||||||